MedTrace Logo

Trident II Revision Outcomes Study

NCT04317586 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2023-12-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to review the performance and success rate of an FDA cleared cementless hip replacement part called the Trident II Tritanium Acetabular Shell. The study will specifically look at the need to revise the hip replacement after 5 years. This will be compared to how much this happens in patients who have hip replacement with similar cementless acetabular shells.

Conditions

  • Arthroplasty, Hip Revision

Interventions

DEVICE

Trident II Tritanium Acetabular Shell for Revision

A hemispherical acetabular shell indicated for cementless application in a previously failed total hip arthroplasty (THA)

Sponsors & Collaborators

  • Stryker Orthopaedics

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-23
Primary Completion
2023-01-27
Completion
2023-01-27
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04317586 on ClinicalTrials.gov